The Efficacy of Botulinum Toxin, Triamcinolone or Fu's needle for the Treatment of refractory Post-Herpetic Neuralgia
Phase 1
Not yet recruiting
- Conditions
- postherpetic neuralgia
- Registration Number
- ITMCTR2200005993
- Lead Sponsor
- Xiao Bao
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Participants were required to have a visual analogue scale (VAS) score 7 at baseline.
Exclusion Criteria
Exclusion criteria included cranial nerves involvement, severe non-PHN pain that might compromise evaluation of pain caused by PHN, and skin disorders that might impair the therapeutic technique. In addition, female patients were required not to be pregnant or lactating
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of botulinum toxin in refractory post-herpetic neuralgia?
How does triamcinolone compare to other corticosteroids for treating post-herpetic neuralgia in clinical trials?
Which biomarkers could predict response to Fu's needle therapy in post-herpetic neuralgia patients?
What are the potential adverse events associated with botulinum toxin and triamcinolone for post-herpetic neuralgia?
How do combination therapies involving botulinum toxin and corticosteroids impact refractory post-herpetic neuralgia outcomes?